ReachRxResearch
Home
Research
Sign Up
Alopecia areata: Emerging therapies and up-to-date management strategies
Back to Research Hub
  1. Home
  2. Research Hub
  3. Alopecia areata: Emerging therapies and…

Alopecia areata: Emerging therapies and up-to-date management strategies

Journal of the American Academy of Dermatology·August 17
DermatologyPractice changingAlopecia AreataNarrative ReviewIntralesional CorticosteroidJAK InhibitorMinoxidilPlatelet-Rich PlasmaTopical CorticosteroidTopical ImmunotherapyMixedBaricitinibDeuruxolitinibMinoxidilRitlecitinib

Summary

View source

What was studied

This review evaluates current and emerging treatments for alopecia areata (AA), covering mild-to-moderate disease (SALT<50) through severe disease (SALT≥50), including JAK inhibitors, topical therapies, immunosuppressants, biologics, and procedural options across patient age groups and comorbidity profiles.

Key findings

FDA-approved oral JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) have reshaped severe AA management; agent selection is guided by age, safety profile, comorbidities, lab monitoring, and insurance coverage. Switching between JAKis may still yield benefit after nonresponse to one agent.

Study limitations

As a narrative review, it does not perform a systematic synthesis or meta-analysis, limiting quantitative comparison of therapies. Evidence for many adjunctive and procedural modalities (PRP, laser, microneedling) is likely heterogeneous and not graded in detail.

Clinical implications

For severe AA (SALT≥50), choose among the three FDA-approved oral JAKis based on patient age, comorbidities, and safety considerations—and consider switching agents after primary nonresponse. For mild-to-moderate AA, start with topical or intralesional corticosteroids ± minoxidil, and use the expanded AASc tool to capture eyebrow/eyelash loss and psychosocial burden beyond scalp SALT score.

Caveats

  • Deuruxolitinib is listed as FDA-approved for severe AA; clinicians should verify current regulatory status, as approval timing relative to publication date (August 2026) should be confirmed.
  • No sample size applies — this is a narrative review with no primary patient cohort. The level of evidence for individual adjunctive and procedural therapies discussed is not explicitly graded within the abstract.
  • Study design is labeled 'Narrative Review' based on abstract language; the paper does not explicitly state a systematic methodology, so evidence grading for individual treatments may vary widely.

Related Questions

Explore related topics

How do baricitinib, ritlecitinib, and deuruxolitinib compare in efficacy and safety for severe alopecia areata?What is the role of the AA Scale for Clinical Use (AASc) compared to SALT score in guiding alopecia areata treatment decisions?Which adjunctive therapies like PRP, microneedling, or topical immunotherapy have the best evidence in alopecia areata?

Publication Details

Year
2026
Journal
Journal of the American Academy of Dermatology
Source
View article
Keep scrolling
More content below.
Up Next